Breast Cancer Clinical Trials in Nashville

Showing 21-40 of 682 trials

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

NCT07558733

The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast cancer.

HR+ HER2- Breast Cancer

Faeth Therapeutics32 participantsStarted Apr 2026

Los Angeles, California, United States • Springfield, Oregon, United States • Nashville, Tennessee, United States

Active Not RecruitingPhase 3< 1 mile

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

NCT04305496

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

Locally Advanced (Inoperable) or Metastatic Breast Cancer

AstraZeneca818 participantsStarted Apr 2020

Gilbert, Arizona, United States • Orange, California, United States • San Francisco, California, United States +212 more locations

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Breast Cancer Trials in Other Cities

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

The PREDICT Registry:

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

Other Conditions in Nashville